International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 4 , Pages 1006-1011 , 15 July 2009

A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931)

  • Jeffrey Allen, M.D.

      Affiliations

    • Departments of Pediatrics and Pathology, New York University Medical Center, New York, NY
    • Corresponding Author InformationReprint requests to: Jeffrey Allen, M.D., New York University Medical Center, 160 East 32nd Street, Hassenfeld Clinic, New York, NY 10016. Tel: (212) 263-9907; Fax (212) 263-8410
    • ,
  • Bernadine Donahue, M.D.

      Affiliations

    • Department of Radiation Oncology, Maimonides Medical Center, Brooklyn, NY
    • ,
  • Minesh Mehta, M.D.

      Affiliations

    • Department of Radiation Oncology, Children's Hospital, Madison, WI
    • ,
  • Douglas C. Miller, M.D., Ph.D.

      Affiliations

    • Departments of Pediatrics and Pathology, New York University Medical Center, New York, NY
    • ,
  • Lucy B. Rorke, M.D.

      Affiliations

    • Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, PA
    • ,
  • Regina Jakacki, M.D.

      Affiliations

    • Department of Pediatric Oncology, Children's Hospital, Pittsburgh, PA
    • ,
  • Patricia Robertson, M.D.

      Affiliations

    • Department of Neurology, C.S. Mott Children's Hospital, Ann Arbor, MI
    • ,
  • Richard Sposto, Ph.D.

      Affiliations

    • Departments of Preventive Medicine and Pediatrics (Children's Hospital Los Angeles), Keck School of Medicine at the University of Southern California, Los Angeles, CA
    • ,
  • Emi Holmes, M.S.

      Affiliations

    • Children's Oncology Group Operations Office, Arcadia, CA
    • ,
  • Gilbert Vezina, M.D.

      Affiliations

    • Department of Radiology, National Children's Medical Center, Washington, DC
    • ,
  • Karin Muraszko, M.D.

      Affiliations

    • Department of Neurosurgery, University of Michigan, Ann Arbor, MI
    • ,
  • Diane Puccetti, M.D.

      Affiliations

    • University of Wisconsin Children's Hospital, Madison, WI
    • ,
  • Michael Prados, M.D.

      Affiliations

    • Department of Neurosurgery, University of California, San Francisco, CA
    • ,
  • Ka-Wah Chan, M.D.

      Affiliations

    • Methodist Children's Hospital of South Texas, San Antonio, TX

Received 1 April 2008 ,Revised 15 September 2008 ,Accepted 28 September 2008.

References 

  1. Zeltzer PM, Boyett , Finlay J, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17:832–845
  2. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202–4208
  3. Hertzberg H, Huk W, Ueberall M, et al. CNS late effects after ALL therapy in childhood. Part I: Neuroradiological findings in long-term survivors of childhood ALL—an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Med Pediatr Oncol. 1997;28:387–400
  4. Allen JC, Walker R, Rosen G. Preradiation high-dose intravenous methotrexate with leucovorin rescue for untreated primary childhood brain tumors. J Clin Oncol. 1988;6:649–653
  5. Schell MJ, McHaney H, Green A, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989;7:754–760
  6. Kuhl J, Muller H, Berthold F, et al. Preradiation chemotherapy of children and young adults with malignant brain tumors: Results of the German pilot trial HIT'88/'89. Klin Padiatr. 1998;210:227–233
  7. Hartsell WF, Gajjar A, Heideman R, et al. Patterns of failure in children with medulloblastoma: Effects of preirradiation chemotherapy. Int J Radiat Oncol Biol Phys. 1997;39:15–24
  8. Back M, Ahern V, Berry M, et al. Importance of radiation time and dose factors on outcome for childhood medulloblastoma. Australas Radiol. 2005;49:298–303
  9. Allen JC, Donahue B, DaRosso R, et al. Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medulloblastoma and other primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys. 1996;36:1155–1161
  10. Prados MD, Edwards M, Chang S, et al. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: Results of a Phase II study. Int J Radiat Oncol Biol Phys. 1999;43:279–285
  11. Jakacki RI, Zelter P, Boyett J, et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: A report of the Childrens Cancer Group. J Clin Oncol. 1995;13:1377–1383
  12. Castello MA, Clerico A, Deb G, et al. High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors. Am J Pediatr Hematol Oncol. 1990;12:297–300
  13. Kalbfleisch J, Prentice R. The statistical analysis of failure time data. New York: John Wiley & Sons; 1980;
  14. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813–820
  15. Allen JC, Helson L, Jereb B. Preradiation chemotherapy for newly diagnosed childhood brain tumors. A modified Phase II trial. Cancer. 1983;52:2001–2006
  16. Mosijczuk AD, Nigro M, Thomas P, et al. Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study. Cancer. 1993;72:2755–2762
  17. Heideman RL, Kovnar E, Kellie S, et al. Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol. 1995;13:2247–2254
  18. Kortmann RD, Timmermann B, Becker G, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: Results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys. 2000;46:269–279
  19. Taylor RE, Bailey C, Robinson K, et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer. 2005;41:727–734
  20. Thames HD, Withers H, Peters L, et al. Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationships. Int J Radiat Oncol Biol Phys. 1982;8:219–226
  21. Barton M. Tables of equivalent dose in 2 Gy fractions: A simple application of the linear quadratic formula. Int J Radiat Oncol Biol Phys. 1995;31:371–378
  22. Carrie C, Muracciole X, Gomez F, et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: Results of the French M-SFOP 98 protocol. Int J Radiat Oncol Biol Phys. 2005;63:711–716
  23. Chin D, Sklar C, Donahue B, et al. Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: A comparison of hyperfractionated versus conventional radiotherapy. Cancer. 1997;80:798–804
  24. Ricardi U, Corrias A, Einaudi S, et al. Thyroid dysfunction as a late effect in childhood medulloblastoma: A comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. Int J Radiat Oncol Biol Phys. 2001;50:1287–1294
  25. Mu X, Bjork-Eriksson T, Nill S, et al. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. Acta Oncol. 2005;44:554–562
  26. Yuh GE, Loredo L, Yonemoto L, et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat medulloblastoma in young children. Cancer J. 2004;10:386–390

 Supported by Children's Oncology Group (COG) grant CA 98543. A complete listing of grant support for research conducted by the Children's Cancer Group and the Pediatric Oncology Group before initiation of the COG grant in 2003 is available online at http://www.childrensoncologygroup.org/admin/grantinfo.htm

 Presented in part at the International Society of Pediatric Neurology (Allen J, Prados M, Donahue B, et al. A phase I/II study for newly diagnosed high risk PNET consisting of neoadjuvant chemotherapy followed by hyperfractionated radiotherapy: Preliminary results of CCG 9931. Neurooncology 2000;2:245).

 Conflict of interest: none.

PII: S0360-3016(08)03472-X

doi: 10.1016/j.ijrobp.2008.09.019

International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 4 , Pages 1006-1011 , 15 July 2009

Article Tools

* Image Usage & Resolution